Document Detail

Relations of Serum COMP to Cardiovascular Risk Factors and Endothelial Function in Patients with Rheumatoid Arthritis Treated with Methotrexate and TNF-α Inhibitors.
MedLine Citation:
PMID:  22660798     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To examine whether serum level of cartilage oligomeric matrix protein (S-COMP) is related to methotrexate (MTX) or to MTX and tumor necrosis factor-α (TNF-α) combination treatment for rheumatoid arthritis (RA); and to investigate whether S-COMP is related to cardiovascular risk factors including endothelial dysfunction and level of anticitrullinated protein antibodies (ACPA) in patients with RA. METHODS: Clinical and laboratory measures, including S-COMP and reactive hyperemic index (RHI), were examined in 55 consecutive patients with RA starting with either MTX (n = 34) or MTX and anti-TNF-α treatment (n = 21) at baseline, and after 6 weeks and 6 months. RESULTS: S-COMP was similar in the 2 treatment regimens during followup. We found a positive relationship between S-COMP at baseline and the use of disease-modifying antirheumatic drugs the last year preceding the study (p = 0.001), and a negative relation to current use of systemic glucocortico - steroids (p = 0.044). The nonsignificant change in S-COMP between baseline and the 6-month followup was positively and independently related to change in ACPA level (p = 0.009). There was no significant association between RHI and level of S-COMP at baseline. CONCLUSION: The cartilage turnover marker S-COMP did not change significantly after 6 months' treatment with MTX with or without a TNF-α inhibitor in patients with RA. The positive association between S-COMP and ACPA suggests that these factors might interact, and could both be contributors to an unknown link between inflammation and cartilage destruction in patients with RA. S-COMP was not related to endothelial function in patients with RA, or to other cardiovascular risk factors studied. Clinical Trials registration number NCT00902005.
Gunnbjørg Hjeltnes; Ivana Hollan; Oystein Førre; Allan Wiik; Torstein Lyberg; Knut Mikkelsen; Stefan Agewall
Related Documents :
17699278 - Mycophenolate mofetil for the treatment of interstitial nephritis.
19336578 - Hla-dr4, dr13(6) and the ancestral haplotype a1b8dr3 are associated with anca-associate...
20707798 - Perioperative morbidity and renal function in young and elderly patients undergoing ele...
313968 - Cold-reacting antinuclear factor in sera from patients with iga nephropathy.
16731468 - First postpacing interval after tachycardia entrainment with correction for atrioventri...
2107078 - Flecainide acetate in atrial flutter and fibrillation. the arrhythmogenic effects.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-1
Journal Detail:
Title:  The Journal of rheumatology     Volume:  -     ISSN:  0315-162X     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Lillehammer Hospital for Rheumatic Diseases, Lillehammer; Oslo University Hospital, Oslo, Norway; and the Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The optimal carrier for BMP-2: a comparison of collagen versus fibrin matrix.
Next Document:  Use of the 28-Joint Count Yields Significantly Higher Concordance Between Different Examiners Than t...